Organogenesis Holdings Inc. Earnings Per Share Disclosure
18. Earnings (Loss) per Share (EPS)
The computation of basic and diluted EPS attributable to the Class A common stockholders was as follows:
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Numerator: |
|
|
|
|
|
|
|
|
|
|||
Net income |
|
$ |
37,032 |
|
|
$ |
861 |
|
|
$ |
4,945 |
|
Accretion of Convertible Preferred Stock to redemption value |
|
|
(540 |
) |
|
|
(412 |
) |
|
|
— |
|
Cumulative dividend on Convertible Preferred Stock |
|
|
(10,830 |
) |
|
|
(1,386 |
) |
|
|
— |
|
Undistributed earnings (loss) |
|
|
25,662 |
|
|
|
(937 |
) |
|
|
4,945 |
|
Undistributed earnings allocated to participating redeemable convertible preferred stock |
|
|
(5,640 |
) |
|
|
— |
|
|
|
— |
|
Net income (loss) attributable to common stockholders |
|
$ |
20,022 |
|
|
$ |
(937 |
) |
|
$ |
4,945 |
|
Denominator: |
|
|
|
|
|
|
|
|
|
|||
Weighted average common shares outstanding —basic |
|
|
126,738,136 |
|
|
|
131,673,278 |
|
|
|
131,231,317 |
|
Dilutive effect of RSUs |
|
|
1,885,566 |
|
|
|
— |
|
|
|
710,813 |
|
Dilutive effect of options |
|
|
1,525,260 |
|
|
|
— |
|
|
|
804,597 |
|
Dilutive effect of PSUs |
|
|
99,450 |
|
|
|
— |
|
|
|
— |
|
Weighted-average common shares outstanding—diluted |
|
|
130,248,412 |
|
|
|
131,673,278 |
|
|
|
132,746,727 |
|
Earnings (loss) per share—basic |
|
$ |
0.16 |
|
|
$ |
(0.01 |
) |
|
$ |
0.04 |
|
Earnings (loss) per share—diluted |
|
$ |
0.15 |
|
|
$ |
(0.01 |
) |
|
$ |
0.04 |
|
For the years ended December 31, 2025, 2024, and 2023, outstanding stock-based awards of 6,482,762, 15,092,510 and 3,147,503, respectively, were excluded from the diluted EPS calculation as they were anti-dilutive. For the years ended December 31, 2025 and 2024, 37,507,755 and 25,133,474, respectively, shares of common stock available upon conversion of Convertible Preferred Stock were excluded from the diluted EPS calculation as they were anti-dilutive.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Feb 29, 2024 | |
| 2022 | Mar 1, 2023 | |
| 2021 | Mar 1, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.